Clearance Summary
TQ HBA1C GEN3 received FDA 510(k) clearance under submission number K102914, sponsored by Roche. The device was reviewed via the Special premarket notification pathway and assigned to the Hematology review panel. The statutory decision date of record is 2011-01-20.
- Submission: K102914
- Applicant / Sponsor: Roche
- Clearance pathway: Special
- Review panel: Hematology
- Device class: Class II
- Regulation citation: 21 CFR 864.7470
- Decision date: 2011-01-20
Classification & Regulation
This clearance is catalogued under FDA product code LCP and 21 CFR 864.7470, within the Hematology review panel as a Class II device.